AT-RvD1 (RvD1) treatment reduced neutrophilic inflammation in the lung
Single-cell suspensions were prepared from lung homogenates. Flow cytometric analysis was performed and (A) representative flow cytometry dot plots from lung homogenates gated on neutrophils (F4/80−/Low, Ly6G+). Neutrophil numbers (B) in the lung demonstrated a marked increase in coinfected mice and a significant reduction with AT-resolvin D1 treatment. (C) Increased neutrophil MPO activity in the lung (D) and increased BAL neutrophil numbers were also redcued by AT-RvD1 treatment. (E) NE activity in the BALF was also assessed, demonstrating an increase in coinfected mice that was reduced by AT-RvD1. (F) Total antimicrobial activity in the BALF was determined using the SP susceptibility assay as described in the ‘Methods’ section. In vitro bacterial growth was increased in the presence of BAL fluid from coinfected mice (compared with SAL), and bacterial growth was significantly lower in cultures containing BALF from AT-RvD1 treated mice (compared with SPIAV-Veh). *P<0.05, one-way ANOVA compared with SPIAV-Veh as indicated.